Neurology Search
Neurology Neurology
narcolepsy
NARCOLEPSY

Narcolepsy is a chronic neurologic sleep disorder wherein the patient have excessive daytime sleepiness and rapid eye movement sleep is dysregulated.

It affects 1 in 1000 individuals, with prevalence of about 0.04% of general population.
The exact cause remains unclear.
Studies suggest a combination of genetic predisposition, abnormal neurotransmitter functioning and abnormal immune modulation.
Symptoms include excessive daytime sleepiness, cataplexy, sleep paralysis, sleep-related hallucinations, automatic behavior, fragmented nocturnal sleep and insomnia.

Patient Education

Patient Education

  • Educate the patients regarding their condition & its implications at the time of diagnosis
  • Regular consultation between the patient & physician is essential to help patients modify their lifestyle & provide optimal management
  • Family support can also improve the course of the disease by helping the patients overcome challenges
  • Inform family members, friends, & co-workers of the signs of narcoleptic spells to help patients lessen possible injuries
  • Advise patients on their activities & jobs
    • Avoid potentially dangerous activities such as operating motor vehicles & machines when feeling sleepy
    • Avoid shift-work, driving, transportation-related jobs, or any work which requires continuous attention for long hours with breaks

Adequate & Regular Nocturnal Sleep

  • Patient should have adequate & regular nocturnal sleep to avoid exacerbating excessive daytime sleepiness
  • Comply with a strict sleep schedule of at least 7-8 hours of sleep at night with a consistent bedtime & time of morning awakening
Editor's Recommendations
Most Read Articles
DAPT cuts recurrent major ischaemia events after minor stroke in POINT
Pearl Toh, 26 Jul 2018
A dual antiplatelet therapy (DAPT) of aspirin and clopidogrel significantly prevented the recurrence of major ischaemic events within 90 days following a minor stroke compared with aspirin alone, albeit this comes at the cost of increased major bleeding risk, according to the POINT* study.
Androgen deprivation therapy does not pose risk of cognitive decline
08 Apr 2018
A 12-month course of androgen deprivation therapy does not appear to negatively affect cognitive function in older men with nonmetastatic prostate cancer (PC), according to a study.